尿路感染及其治疗药物的研究进展

被引:36
作者
郭薇
孙凤军
邱学文
夏培元
机构
[1] 第三军医大学第一附属医院药剂科
关键词
尿路感染; 尿路致病菌; 药物治疗; 疫苗研发;
D O I
暂无
中图分类号
R691.3 [泌尿生殖系感染];
学科分类号
100221 [泌尿外科学];
摘要
目的:了解尿路感染的病理机制和治疗药物的研究进展,以期为其临床诊断、药物治疗和研发提供参考。方法:查阅近年来国内外相关文献,就尿路感染的类型、病理机制和治疗药物进行归纳和总结。结果与结论:尿路感染主要为尿路致病菌感染,其治疗药物的研究方向主要为以细菌附着、细菌毒素和蛋白酶、铁载体、脲酶、菌毛为靶标的疫苗或小分子药物。以细菌附着为靶标的疫苗可很好地阻断病原体与机体的相互作用,降低尿路感染的发生率;以细菌毒素和蛋白酶为靶标的疫苗的临床疗效仍有待进一步评估;以铁载体为靶标的疫苗可减缓疾病进展和减弱细菌定植;以脲酶为靶标的小分子药物具有一定疗效的同时也存在较严重的副作用;以菌毛为靶标的小分子药物通过阻断尿路感染动物模型的病原体在膀胱上的定植和侵入,能较好并快速地发挥预防和治疗尿路感染的作用。黏附素Fim H的抗体已进入了Ⅰ期临床试验阶段,但Pilicides、Mannosides和靶向于菌毛、铁载体以及其他毒力因素的疫苗等仍处于实验研究或临床前研究阶段。
引用
收藏
页码:2441 / 2444
页数:4
相关论文
共 8 条
[1]
In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections.[J].Nastaran Sadat Savar;Ali Jahanian-Najafabadi;Mehdi Mahdavi;Mohammad Ali Shokrgozar;Anis Jafari;Saeid Bouzari.Journal of Biotechnology.2014,
[2]
Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.[J].David M. Livermore;Shazad Mushtaq.Journal of Antimicrobial Chemotherapy.2013, 8
[3]
Immunization with the Yersiniabactin Receptor, FyuA, Protects against Pyelonephritis in a Murine Model of Urinary Tract Infection [J].
Brumbaugh, Ariel R. ;
Smith, Sara N. ;
Mobley, Harry L. T. .
INFECTION AND IMMUNITY, 2013, 81 (09) :3309-3316
[4]
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination [J].
Zhanel, George G. ;
Lawson, Christopher D. ;
Adam, Heather ;
Schweizer, Frank ;
Zelenitsky, Sheryl ;
Lagace-Wiens, Philippe R. S. ;
Denisuik, Andrew ;
Rubinstein, Ethan ;
Gin, Alfred S. ;
Hoban, Daryl J. ;
Lynch, Joseph P., III ;
Karlowsky, James A. .
DRUGS, 2013, 73 (02) :159-177
[5]
Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.[J].Thomas J. Hannan;Makrina Totsika;Kylie J. Mansfield;Kate H. Moore;Mark A. Schembri;Scott J. Hultgren.FEMS Microbiol Rev.2012, 3
[6]
Urease inhibitors as potential drugs for gastric and urinary tract infections: a patent review [J].
Kosikowska, Paulina ;
Berlicki, Lukasz .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (06) :945-957
[7]
Complicated urinary tract infections [J].
Lichtenberger P. ;
Hooton T.M. .
Current Infectious Disease Reports, 2008, 10 (6) :499-504
[8]
Requirement of Rho-family GTPases in the invasion of type 1-piliated uropathogenic Escherichia coli [J].
Martinez, JJ ;
Hultgren, SJ .
CELLULAR MICROBIOLOGY, 2002, 4 (01) :19-28